Focus: US FDA warnings shrink market cap for Indian drug makers

6 January 2016

Market capitalization of Indian drug makers has taken a hit as the US Food and Drug Administraton rains warnings against manufacturing practices, The Pharma Letter’s Anjali Shukla tracks the dent.

Shares in Cadila Healthcare (BOM:532321) plunged 17% on the Bombay Stock Exchange on December 31 after the company received a warning letter from the US FDA for violating manufacturing standards at its Moraiya formulation plant and Ahmedabad oncology API (active pharmaceutical ingredient) facility.

On December 19, Sun Pharmaceutical Industries (BOM:524715), the largest Indian drug maker, was slapped a warning letter from the FDA for violating manufacturing standards at its Halol plant in the western Indian state of Gujarat. The company has been trying to fix the issues at that plant for over a year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK